Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

Publikation

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

Wissenschaftlicher Artikel/Review - 09.05.2022

Dimopoulos Meletios A, Richardson Paul G, Bahlis Nizar, Grosicki Sebastian, Cavo Michele, Beksac Meral, Legieć Wojciech, Liberati Anna Marina, Goldschmidt Hartmut, Belch Andrew, Magen Hila, Larocca Alessandra, Laubach Jacob, Petrucci Maria Teresa, Reece Donna, White Darrell, Mateos Maria-Victoria, Špička Ivan, Lazaroiu Mihaela, Berdeja Jesus G, Kaufman Jonathan L, Jou Ying-Ming, Ganetsky Alex, Popa McKiver Mihaela, Lonial Sagar, Weisel Katja, Driessen Christoph

Zitation

Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksac M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, Driessen C. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9:e403-e414.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet Haematol 2022; 9

Veröffentlichungsdatum

09.05.2022

eISSN (Online)

2352-3026

Seiten

e403-e414

Kurzbeschreibung/Zielsetzung

Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in patients with newly diagnosed multiple myeloma who are ineligible for haematopoietic stem-cell transplantation (HSCT).